Evaluation and performance of a newly developed patient-reported outcome instrument for diarrhea-predominant irritable bowel syndrome in a clinical study population.

导出 OA

翻译打印收藏纠错

作者： Leticia,Delgado-Herrera ^[1] ; Kathryn,Lasch ^[2] ; Bernhardt,Zeiher ^[3] ; Anthony J,Lembo ^[4] ; Douglas A,Drossman ^[5] ; Benjamin,Banderas ^[6] ; Kathleen,Rosa ^[6] ; Christopher,Lademacher ^[3] ; Rob,Arbuckle ^[7]

作者单位： Astellas Pharma Global Development, Inc., One Astellas Way, Northbrook, IL 60062, USA. ^[1] Pharmerit International, Newton, MA, USA. ^[2] Astellas Pharma Global Development, Inc., Northbrook, IL, USA. ^[3] Beth Israel Deaconess Medical Center, Boston, MA, USA. ^[4] Drossman Center for the Education and Practice of Biopsychosocial Care, UNC Center for Functional GI and Motility Disorders, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA, and Drossman Gastroenterology PLLC, Chapel Hill, NC, USA. ^[5] Adelphi Values, Boston, MA, USA. ^[6] Adelphi Values, Bollington, Cheshire, UK. ^[7]

关键词 IBS Global Assessment of Improvement IBS Patient Global Impression of Severity diarrhea-predominant irritable bowel syndrome psychometric responsiveness

DOI 10.1177/1756283X17726018

PMID 28932269

发布时间 2022-04-09

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交